In recent years, ophthalmic drugs have enjoyed a relatively high probability of success in progressing from Phase I clinical trials to market, estimated in 2015 at ~30%. This clinical success is driven by good preclinical models, especially for wet AMD. In 2016 we developed a mouse model for mimicking the oxidative stress, inflammation and cell death characteristics of the more prevalent form of AMD – dry AMD. This model has opened up both fundamental science and commercial opportunities to better understand and develop new strategies for combating dry AMD. In the Clear Vision Research Lab we are exploring a number of therapeutic options, developed at ANU and by commercial partners, which include gene-based therapies, non-invasive therapeutics (including the use of low-level laser therapy using red light) and novel compounds. We are actively engaging with commercial partners to help develop strategies to slow the progression of retinal degenerations, by targeting inflammation and oxidative stress processes.